Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
25 GBX | -0.99% | -5.66% | +61.29% |
Apr. 18 | Renalytix chief business officer to become president | AN |
Apr. 18 | Renalytix Names Chief Business Officer as President | MT |
Financials (USD)
Sales 2024 * | 4M | Sales 2025 * | 18M | Capitalization | 48.93M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -26M | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.72 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.33% |
Latest transcript on Renalytix Plc
1 day | -0.98% | ||
1 week | -8.18% | ||
Current month | +17.44% | ||
1 month | -22.31% | ||
3 months | -33.99% | ||
6 months | -32.67% | ||
Current year | +62.90% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
James Sterling
DFI | Director of Finance/CFO | 54 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 25 | -0.99% | 125 784 |
24-05-13 | 25.25 | -0.98% | 37,054 |
24-05-10 | 25.5 | 0.00% | 83,781 |
24-05-09 | 25.5 | -3.77% | 574,560 |
24-05-08 | 26.5 | 0.00% | 98,300 |
Delayed Quote London S.E., May 13, 2024 at 11:35 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+62.90% | 48.93M | |
-42.86% | 2.82B | |
+20.51% | 1.91B | |
-1.13% | 1.65B | |
+27.00% | 1.25B | |
-14.07% | 988M | |
-20.60% | 910M | |
+0.88% | 786M | |
-24.34% | 634M | |
+8.73% | 507M |
- Stock Market
- Equities
- RENX Stock